Transcatheter aortic valve implantation and transient left ventricular dysfunction

Transcatheter aortic valve implantation (TAVI) triggers a transient, reversible decline in ventricular contractile function within the first six to 24 hours post-procedure. Dr. Philip McCarthy, an early adopter of the technique at King's College London, identifies this phenomenon as a period of myocardial stunning, likely exacerbated by rapid ventricular pacing and subendocardial ischemia during valve deployment. While cardiac output increases due to the relief of chronic pressure overload, the observed dip in myocardial performance necessitates closer clinical monitoring for signs of heart failure, such as peripheral edema or respiratory distress, during the immediate recovery phase. Managing these patients with targeted heart failure therapies and judicious fluid management can mitigate these early complications. Looking forward, the field is shifting toward more rigorous case selection to avoid futile interventions in high-risk patients while simultaneously advancing delivery technology to improve procedural safety and outcomes.